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CORRESPONDENCE
Insulin receptor substrate-1 
Gly972Arg variant and type 2  
diabetes mellitus
To the Editor: In their article, Vergotine et al.[1] concluded that 
‘the Gly972Arg variant may not aid diabetes risk evaluation in 
this setting’. In fact, the insulin receptor substrate-1 Gly972Arg 
variant is widely studied in terms of its relationship to diabetes 
mellitus. Different observations have been made in different 
settings. In a report from Mexico, Burguete-Garcia et al.[2] found 
‘participation of Gly972Arg polymorphism of IRS1 in the genetic 
susceptibility to TD2 in Mexican population’. An interesting 
point is that there are many possible genetic polymorphisms that 
can relate to diabetes mellitus. However, a polymorphism study 
alone cannot tell the exact relationship. In a previous study from 
Mexico,[3] a polygenic polymorphism effect on diabetes could be 
confirmed.
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